Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
09
10
2020
accepted:
31
03
2021
pubmed:
20
5
2021
medline:
21
10
2021
entrez:
19
5
2021
Statut:
ppublish
Résumé
Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but both imaging and current biomarkers are ineffective post-surgery. NETest, a multigene blood biomarker, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would predict recurrence. This was a multicenter evaluation of surgically treated primary NETs (n = 153). Blood sampling was performed at day 0 and postoperative day (POD) 30. Follow-up included computed tomography/magnetic resonance imaging (CT/MRI), and messenger RNA (mRNA) quantification was performed by polymerase chain reaction (PCR; NETest score: 0-100; normal ≤20). Statistical analyses were performed using the Mann-Whitney U-test, Chi-square test, Kaplan-Meier survival, and area under the receiver operating characteristic curve (AUROC), as appropriate. Data are presented as mean ± standard deviation. The NET cohort (n = 153) included 57 patients with pancreatic cancer, 62 patients with small bowel cancer, 27 patients with lung cancer, 4 patients with duodenal cancer, and 3 patients with gastric cancer, while the surgical cohort comprised patients with R0 (n = 102) and R1 and R2 (n = 51) resection. The mean follow-up time was 14 months (range 3-68). The NETest was positive in 153/153 (100%) samples preoperatively (mean levels of 68 ± 28). In the R0 cohort, POD30 levels decreased from 62 ± 28 to 22 ± 20 (p < 0.0001), but remained elevated in 30% (31/102) of patients: 28% lung, 29% pancreas, 27% small bowel, and 33% gastric. By 18 months, 25/31 (81%) patients with a POD30 NETest >20 had image-identifiable recurrence. An NETest score of >20 predicted recurrence with 100% sensitivity and correlated with residual disease (Chi-square 17.1, p < 0.0001). AUROC analysis identified an AUC of 0.97 (p < 0.0001) for recurrence-prediction. In the R1 (n = 29) and R2 (n = 22) cohorts, the score decreased (R1: 74 ± 28 to 45 ± 24, p = 0.0012; R2: 72 ± 24 to 60 ± 28, p = non-significant). At POD30, 100% of NETest scores were elevated despite surgery (p < 0.0001). The preoperative NETest accurately identified all NETs (100%). All resections decreased NETest levels and a POD30 NETest score >20 predicted radiologically recurrent disease with 94% accuracy and 100% sensitivity. R0 resection appears to be ineffective in approximately 30% of patients. NET mRNA blood levels provide early objective genomic identification of residual disease and may facilitate management.
Identifiants
pubmed: 34008138
doi: 10.1245/s10434-021-10021-1
pii: 10.1245/s10434-021-10021-1
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Messenger
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
7506-7517Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68:471–87. https://doi.org/10.3322/caac.21493 .
doi: 10.3322/caac.21493
pubmed: 30295930
Clift AK, Kidd M, Bodei L, et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2020;110:444–76. https://doi.org/10.1159/000503721 .
doi: 10.1159/000503721
pubmed: 31557758
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42. https://doi.org/10.1001/jamaoncol.2017.0589 .
doi: 10.1001/jamaoncol.2017.0589
pubmed: 28448665
pmcid: 5824320
Shen C, Dasari A, Xu Y, et al. Pre-existing symptoms and healthcare utilization prior to diagnosis of neuroendocrine tumors: a seer-medicare database study. Sci Rep. 2018;8:16863. https://doi.org/10.11038/s41598-16018-35340-16864 .
doi: 10.11038/s41598-16018-35340-16864
pubmed: 30442902
pmcid: 6238007
Shen C, Chu Y, Halperin DM, et al. Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients. Oncologist. 2017;22:1451–62. https://doi.org/10.1634/theoncologist.2017-0149 .
doi: 10.1634/theoncologist.2017-0149
pubmed: 28642335
pmcid: 5728018
Capdevila J, Bodei L, Davies P, et al. Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms. Neuroendocrinology. 2019;108:18–25.
doi: 10.1159/000493319
Ambrosini V, Nanni C, Fanti S. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging. PET Clin. 2014;9:323–9.
doi: 10.1016/j.cpet.2014.03.008
Marotta V, Zatelli MC, Sciammarella C, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer. 2018;25:R11–29. https://doi.org/10.1530/ERC-1517-0269 .
doi: 10.1530/ERC-1517-0269
pubmed: 29066503
Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14:656–69. https://doi.org/10.1038/s41574-41018-40082-41575 .
doi: 10.1038/s41574-41018-40082-41575
pubmed: 30158549
Sansone A, Lauretta R, Vottari S, et al. Specific and non-specific biomarkers in neuroendocrine gastroenteropancreatic tumors. Cancers (Basel). 2019;11:1113. https://doi.org/10.3390/cancers11081113 .
doi: 10.3390/cancers11081113
pmcid: 6721814
Pulvirenti A, Rao D, McIntyre CA, et al. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). 2019;21:612–8. https://doi.org/10.1016/j.hpb.2018.1009.1016 (Epub 2018 Oct 1023).
doi: 10.1016/j.hpb.2018.1009.1016
pubmed: 30366884
Partelli S, Mazza M, Andreasi V, et al. Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. Surgery. 2019;166:157–63.
doi: 10.1016/j.surg.2019.04.003
Chan DL, Moody L, Segelov E, et al. Follow-up for resected gastroenteropancreatic neuroendocrine tumours: a practice survey of the commonwealth neuroendocrine tumour collaboration (commnets) and the north american neuroendocrine tumor society (NANETS). Neuroendocrinology. 2018;107:32–41.
doi: 10.1159/000488394
Oberg K, Krenning E, Sundin A, et al. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect. 2016;5:174–87. https://doi.org/10.1530/EC-1516-0043 .
doi: 10.1530/EC-1516-0043
pubmed: 27582247
pmcid: 5045519
Partelli S, Andreasi V, Muffatti F, Schiavo Lena M, Falconi M. Circulating neuroendocrine gene transcripts (NETest): a postoperative strategy for early identification of the efficacy of radical surgery for pancreatic neuroendocrine tumors. Ann Surg Oncol. 2020;6:020–08425.
Oberg K, Modlin I, DeHerder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435–e446. https://doi.org/10.1016/S1470-2045(15)00186-2
doi: 10.1016/S1470-2045(15)00186-2
Laskaratos FM, Liu M, Malczewska A, et al. Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection. Endocrine. 2020;69(2):430–40.
doi: 10.1007/s12020-020-02289-2
Genc C, Jilesen AP, Nieveen van Dijkum E, et al. Measurement of circulating transcript levels (netest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumours. J Surg Oncol. 2018;118: 37-48.
van Treijen MJC, van der Zee D, Heeres BC, et al. Blood Molecular Genomic analysis predicts the disease course of GEP NET patients: a validation study of the predictive value of the NETest®. Neuroendocrinology. 2020. https://doi.org/10.1159/000509091
Filosso PL, Oberg K, Malczewska A, et al. Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy. Eur J Cardiothorac Surg. 2020;57(6):1195–202.
doi: 10.1093/ejcts/ezaa018
van Treijen MJC, Korse CM, van Leeuwaarde RS, et al. Blood transcript profiling for the detection of neuroendocrine tumors: results of a large independent validation study. Front Endocrinol (Lausanne). 2018;9:740. https://doi.org/10.3389/fendo.2018.00740.eCollection02018 .
doi: 10.3389/fendo.2018.00740.eCollection02018
pubmed: 30564197
pmcid: 6288275
Oberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31:202–12. https://doi.org/10.1016/j.annonc.2019.1011.1003 .
doi: 10.1016/j.annonc.2019.1011.1003
pubmed: 31959337
Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. NET blood transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive. Neuroendocrinology. 2017;104:170–82.
doi: 10.1159/000446025
Shah MH, Kulke MH, Goldner WS, et al. NCCN Guidelines: neuroendocrine and adrenal tumors, version 3.2018 - Sept 11. J Natl Compr Canc Netw. 2018:693–702. https://doi.org/10.6004/jnccn.2018.0056 .
Salazar R, Wiedenmann B, Rindi G, Ruszniewski P. ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2012;95:71–3. https://doi.org/10.1159/000335600 .
doi: 10.1159/000335600
pubmed: 22262042
Filosso P, Kidd M, Roffinella M, et al. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumors (BPNET) and as a tool to evaluate surgical resection and disease progression. Eur J Cardiothorac Surg. 2018;53:631–9.
doi: 10.1093/ejcts/ezx386
Kidd M, Drozdov IA, Matar S, et al. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS One. 2019;14:e0218592.
doi: 10.1371/journal.pone.0218592
Maurizi G, Ibrahim M, Andreetti C, et al. Long-term results after resection of bronchial carcinoid tumour: evaluation of survival and prognostic factors. Interact Cardiovasc Thorac Surg. 2014;19:239–44.
doi: 10.1093/icvts/ivu109
Zhang XF, Wu Z, Cloyd J, et al. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. Surgery. 2019;165:548–56.
doi: 10.1016/j.surg.2018.08.015
Lamarca A, Clouston H, Barriuso J, et al. Follow-up recommendations after curative resection of well-differentiated neuroendocrine tumours: review of current evidence and clinical practice. J Clin Med. 2019;8(10):1630.
doi: 10.3390/jcm8101630
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60. https://doi.org/10.1016/j.annonc.2020.1003.1304 .
doi: 10.1016/j.annonc.2020.1003.1304
pubmed: 32272208
Grobmyer SR, Vogel SB, McGuigan JE, Copeland EM, Hochwald SN. Reoperative surgery in sporadic Zollinger-Ellison Syndrome: longterm results. J Am Coll Surg. 2009;208: 718-722; discussion 722-714.
Malczewska A, Bodei L, Kidd M, Modlin IM. Blood mRNA measurement (NETest) for neuroendocrine tumor diagnosis of image-negative liver metastatic disease. J Clin Endocrinol Metab. 2019;104:867–72. https://doi.org/10.1210/jc.2018-01804 .
doi: 10.1210/jc.2018-01804
pubmed: 30358858
Malczewska A, Witkowska M, Wojcik-Giertuga M, et al. Prospective Evaluation of the NETest as a liquid biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumours: An ENETS Centre of Excellence Experience. Neuroendocrinology. 2021;111(4):304–19. https://doi.org/10.1159/000508106 .
Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6:7686.
doi: 10.1038/ncomms8686
Kidd M, Modlin I, Bodei L, Drozdov I. Decoding the molecular and mutational ambiguities of gastroenteropancreatic neuroendocrine neoplasm pathobiology. Cell Mol Gastroenterol Hepatol. 2015;1:131–53.
doi: 10.1016/j.jcmgh.2014.12.008
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.1002.1013 .
doi: 10.1016/j.cell.2011.1002.1013
pubmed: 21376230
Liu E, Paulson S, Gulati A, et al. Assessment of NETest Clinical utility in a US Registry-based study. The Oncologist. 2019;24:783–90.
doi: 10.1634/theoncologist.2017-0623
Modlin IM, Frilling A, Salem RR, et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 2016;159:336–47. https://doi.org/10.1016/j.surg.2015.1006.1056 .
doi: 10.1016/j.surg.2015.1006.1056
pubmed: 26456125
Goretzki PE, Mogl MT, Akca A, Pratschke J. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract. Rev Endocr Metab Disord. 2018;19:169–78.
doi: 10.1007/s11154-018-9469-9
Bodei L, Schöder H, Baum RP, et al. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020;21:e431–43.
doi: 10.1016/S1470-2045(20)30323-5
Bodei L, Kidd MS, Singh A, et al. PRRT Genomic Signature in Blood for Prediction of 177Lu-octreotate Efficacy. Eur J Nucl Med Mol Imaging. 2018;45:1155–69.
doi: 10.1007/s00259-018-3967-6
Modlin IM, Kidd M, Malczewska A, et al. The NETest: the clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors. Endocrinol Metab Clin North Am. 2018;47:485–504. https://doi.org/10.1016/j.ecl.2018.1005.1002 .
doi: 10.1016/j.ecl.2018.1005.1002
pubmed: 30098712
pmcid: 6716518
Kidd M, Kitz A, Drozdov I, Modlin I. Neuroendocrine tumor omic gene cluster analysis amplifies the prognostic accuracy of the NETest. Neuroendocrinology. 2020. https://doi.org/10.1159/000508573 .
Strosberg J, Casciano R, Stern L, et al. United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol. 2013;19:2348–54. https://doi.org/10.3748/wjg.v2319.i2315.2348 .
doi: 10.3748/wjg.v2319.i2315.2348
pubmed: 23613628
pmcid: 3631986
Modlin IM, Aslanian H, Bodei L, Drozdov I, Kidd M. A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by PPIs. Endocr Connect. 2014;3(4):215–23.
doi: 10.1530/EC-14-0100
Partelli S, Falconi M. ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET). Ann Surg Oncol. 2020;27:3937–8.
doi: 10.1245/s10434-020-08464-z